ArticleDrug delivery and translational research2026
Multi-component microneedle drug delivery system of sanfu herbal patch for allergic asthma in rats.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
A dissolvable microneedle system (SFP-MNs) loaded with seven principal Sanfu Herbal Patch components was developed to assess transdermal delivery feasibility and therapeutic efficacy in a rat model of allergic asthma. SFP-MNs were fabricated using a two-step centrifugation-assisted template molding method and characterized in terms of morphology, mechanical strength, skin penetration capability, and in vitro drug release behavior. An ovalbumin (OVA)-induced allergic asthma model was established in Sprague-Dawley (SD) rats to investigate the in vivo performance of the microneedles. Pulmonary interstitial fluid was continuously sampled by microdialysis following transdermal administration, and drug concentrations were quantified using UPLC-MS/MS. Pharmacodynamic responses were evaluated by measuring histamine (HIS), immunoglobulin E (IgE), interleukin-10 (IL-10), and tumor necrosis factor-α (TNF-α) levels using ELISA, together with histopathological examination by hematoxylin and eosin (HE) and periodic acid-Schiff (PAS) staining. A pharmacokinetic-pharmacodynamic (PK-PD) model was subsequently established to characterize the relationship between drug exposure and therapeutic response. The prepared SFP-MNs exhibited excellent mechanical properties, efficient skin penetration, and sustained drug release. In vivo, SFP-MNs achieved effective transdermal delivery of the encapsulated components and produced superior therapeutic outcomes compared with an equivalent-dose conventional Sanfu Herbal Patch gel. Specifically, high-dose SFP-MNs markedly alleviated airway inflammation, reduced inflammatory biomarker levels, and attenuated pulmonary histopathological injury in allergic asthmatic rats. These findings demonstrate that SFP-MNs represent a promising transdermal drug delivery platform with the potential to replace conventional Sanfu Herbal Patch for the treatment of allergic asthma while providing sustained drug release and improved therapeutic efficacy.
Indexed as
Identifiers
42570969What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.